Skip to main content

"This reduces by more than 25% the effect of these bonds on our quarterly net results, where the change in the underlying value of the conversion shares is responsible for the large non-cash financial adjustments under IFRS."

- Dr Sijmen de Vries, Pharming’s CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline